Gonadal hormones and cognitive aging: A midlife perspective

Women's Health

Volumn 7, Issue 1, 2011, Pages 81-93

  Henderson, Victor W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cognition; dementia; estrogen; memory; menopause; testosterone

Indexed keywords

AMYLOID BETA PROTEIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; SEX HORMONE; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

AGING; ALZHEIMER DISEASE; BRAIN DEVELOPMENT; CAUSAL ATTRIBUTION; CLIMACTERIUM; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DISEASE MARKER; DRUG EFFICACY; EPISODIC MEMORY; ESTRADIOL BLOOD LEVEL; HORMONAL THERAPY; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; MEMORY DISORDER; MENOPAUSAL SYNDROME; MENTAL PERFORMANCE; MENTAL TEST; MIDDLE AGED; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY CYCLE; OVULATION INHIBITION; POSTMENOPAUSE; RECALL; REPRODUCTIVE HEALTH; REVIEW; SEMANTIC MEMORY; TESTOSTERONE BLOOD LEVEL; WOMEN'S HEALTH;

AGING; BRAIN; COGNITION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; MEMORY DISORDERS; MENOPAUSE; MENTAL RECALL; MIDDLE AGED; PROGESTERONE; TESTOSTERONE;

EID: 78650634396     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.10.87     Document Type: Review

References (102)

1. Gold EB, Bromberger J, Crawford S et al.: Factors associated with age at natural menopause in a multiethnic sample of midlife women. Am. J. Epidemiol. 153, 865-874 (2001).
2. Soules MR, Sherman S, Parrott E et al.: Executive summary: stages of reproductive aging workshop (STRAW). Fertil. Steril. 76, 874-878 (2001). (Pubitemid 33031310)
3. Guthrie JR, Dennerstein L, Taffe JR, Lehert P, Burger HG: The menopausal transition: a 9-year prospective population-based study. The Melbourne Womens Midlife Health Project. Climacteric 7, 375-389 (2004).
4. Burger HG, Hale GE, Robertson DM, Dennerstein L: A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Womens Midlife Health Project. Hum. Reprod. Update 13, 559-565 (2007).
5. Prior JC: Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation. Endocrine 26, 297-300 (2005).
6. Davison S, Bell R, Donath S, Montalto J, Davis SR: Androgen levels in adult females: changes with age, menopause and oophorectomy. J. Clin. Endocrinol. Metab. 90, 3847-3853 (2005).
7. Hamilton D: The Monkey Gland Affair. Chatto & Windus, London, UK (1986).
8. Wilson RA: Feminine Forever. M Evans and Company, NY, USA (1966).
9. Hersh AL, Stefanick ML, Stafford RS: National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291, 47-53 (2004).
10. Caldwell BM: An evaluation of psychological effects of sex hormone administration in aged women. II. Results of therapy after eighteen months. J. Gerontol. 9, 168-174 (1954).
11. Fillit H, Weinreb H, Cholst I et al.: Observations in a preliminary open trial of estradiol therapy for senile dementia- Alzheimers type. Psychoneuroendocrinology 11, 337-345 (1986).
12. Honjo H, Ogino Y, Naitoh K et al.: In vivo effects by estrone sulfate on the central nervous system senile dementia (Alzheimers type). J. Steroid Biochem. 34, 521-525 (1989).
13. Ohkura T, Isse K, Akazawa K et al.: Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. J. 41, 361-371 (1994).
14. Birge SJ: The role of estrogen deficiency in the aging central nervous system. In: Treatment of the Postmenopausal Woman: Basic and Clinical Aspects, Lobo RA (Ed.). Raven Press, NY, USA 153-157 (1994).
15. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG: Estrogen replacement therapy in older women: comparisons between Alzheimers disease cases and nondemented control subjects. Arch. Neurol. 51, 896-900 (1994).
16. Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimers disease in women. Am. J. Epidemiol. 140, 256-261 (1994).
17. Squire LR: Memory and brain systems: 1969-2009. J. Neurosci. 29, 12711-12716 (2009).
18. Andreano JM, Cahill L: Sex influences on the neurobiology of learning and memory. Learn. Mem. 16, 248-266 (2009).
19. Weintraub S, Salmon D, Mercaldo N et al.: The Alzheimers Disease Centers Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis. Assoc. Disord. 23, 91-101 (2009).
20. Welsh K, Butters N, Hughes J, Mohs R, Heyman A: Detection of abnormal memory decline in mild cases of Alzheimers disease using CERAD neuropsychological measures. Arch. Neurol. 48, 278-281 (1991).
21. Kukull WA, Higdon R, Bowen JD et al.: Dementia and Alzheimer disease incidence: a prospective cohort study. Arch. Neurol. 59, 1737-1746 (2002).
22. Petersen RC, Smith GE, Waring SC et al.: Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308 (1999).
23. Stern Y: Cognitive reserve and Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (Suppl. 3), S69-S74 (2006). (Pubitemid 44265854)
24. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.). 82, 239-259 (1991).
25. Mosconi L, Mistur R, Switalski R et al.: FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimers disease. Eur. J. Nucl. Med. Mol. Imaging 36, 811-822 (2009).
26. Jack CR Jr, Knopman DS, Jagust WJ et al.: Hypothetical model of dynamic biomarkers of the Alzheimers pathological cascade. Lancet Neurol. 9, 119-128 (2010).
27. González M, Cabrera-Socorro A, Pérez-García CG et al.: Distribution patterns of estrogen receptor a and b in the human cortex and hippocampus during development and adulthood. J. Comp. Neurol. 503, 790-802 (2007).
28. Shughrue PJ, Scrimo PJ, Merchenthaler I: Estrogen binding and estrogen receptor characterization (ERa and ERb) in the cholinergic neurons of the rat basal forebrain. Neuroscience 96, 41-49 (2000).
29. Gibbs RB, Mauk R, Nelson D, Johnson DA: Donepezil treatment restores the ability of estradiol to enhance cognitive performance in aged rats: evidence for the cholinergic basis of the critical period hypothesis. Horm. Behav. 56, 73-83 (2009).
30. Woolley CS, McEwen BS: Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J. Comp. Neurol. 336, 293-306 (1993).
31. Foy MR, Henderson VW, Berger TW, Thompson RF: Estrogen and neural plasticity. Curr. Dir. Psychol. Sci. 9, 148-152 (2000).
32. Foy MR, Akopian G, Thompson RF: Progesterone regulation of synaptic transmission and plasticity in rodent hippocampus. Learn. Mem. 15, 820-822 (2008).
33. Tanapat P, Hastings NB, Gould E: Ovarian steroids influence cell proliferation in the dentate gyrus of the adult female rat in a dose- and time-dependent manner. J. Comp. Neurol. 481, 252-265 (2005).
34. Petanceska SS, Nagy G, Frail D, Gandy S: Ovariectomy and 17b-estradiol modulate the levels of Alzheimers amyloid b peptides in brain. Neurology 54, 2212-2217 (2000).
35. Barron AM, Cake M, Verdile G, Martins RN: Ovariectomy and 17b-estradiol replacement do not alter b-amyloid levels in sheep brain. Endocrinology 150, 3228-3236 (2009).
36. Zheng H, Xu H, Uljon SN et al.: Modulation of Ab peptides by estrogen in mouse models. J. Neurochem. 80, 191-196 (2002)
37. Yue X, Lu M, Lancaster T et al.: Brain estrogen deficiency accelerates Ab plaque formation in an Alzheimers disease animal model. Proc. Natl. Acad. Sci. USA 102, 19198-19203 (2005).
38. Carroll JC, Rosario ER, Chang L et al.: Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 27, 13357-13365 (2007).
39. Amtul Z, Wang L, Westaway D, Rozmahel RF: Neuroprotective mechanism conferred by 17b-estradiol on the biochemical basis of Alzheimers disease. Neuroscience 169, 781-786 (2010).
40. Golub MS, Germann SL, Mercer M et al.: Behavioral consequences of ovarian atrophy and estrogen replacement in the APPswe mouse. Neurobiol. Aging 29, 1512-1523 (2008).
41. Alvarez-De-La-Rosa M, Silva I, Nilsen J et al.: Estradiol prevents neural tau hyperphosphorylation characteristic of Alzheimers disease. Ann. NY Acad. Sci. 1052, 210-224 (2005).
42. Henderson VW, Brinton RD: Menopause and mitochondria: windows into estrogen effects on Alzheimers disease risk and therapy. Prog. Brain Res. 182, 77-96 (2010).
43. Henderson VW: Hormone therapy and Alzheimers disease: benefit or harm? Expert Opin. Pharmacother. 5, 389-406 (2004).
44. Zhao L, Brinton RD: Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimers disease. BMC Neuroscience 13, 24 (2006).
45. Chetkowski RJ, Meldrum DR, Steingold KA et al.: Biologic effects of transdermal estradiol. N. Engl. J. Med. 314, 1615-1620 (1986).
46. Vongpatanasin W, Tuncel M, Wang Z et al.: Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. J. Am. Coll. Cardiol. 41, 1358-1363 (2003).
47. Protopopescu X, Butler T, Pan H et al.: Hippocampal structural changes across the menstrual cycle. Hippocampus 18, 985-988 (2008).
48. Hatta T, Nagaya K: Menstrual cycle phase effects on memory and Stroop task performance. Arch. Sex. Behav. 38, 821-827 (2009).
49. Mordecai K, Rubin L, Maki P: Effects of menstrual cycle phase and oral contraceptive use on verbal memory. Horm. Behav. 54, 286-293 (2008).
50. Sherwin BB, Tulandi T: Add-back estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J. Clin. Endocrinol. Metab. 81, 2545-2549 (1996).
51. Mitchell ES, Woods NF: Midlife womens attributions about perceived memory changes: observations from the Seattle Midlife Womens Health Study. J. Womens Health Gend. Based Med. 10, 351-362 (2001).
52. Xu J, Bartoces M, Neale AV et al.: Natural history of menopause symptoms in primary care patients: a MetroNet study. J. Am. Board Fam. Pract. 18, 374-382 (2005).
53. Weber M, Mapstone M: Memory complaints and memory performance in the menopausal transition. Menopause 16, 694-700 (2009).
54. Henderson VW, Sherwin BB: Surgical versus natural menopause: cognitive issues. Menopause 14, 572-579 (2007).
55. Dennerstein L, Smith AMA, Morse CA et al.: Menopausal symptoms in Australian women. Med. J. Aust. 159, 232-236 (1993).
56. Henderson VW, Dudley EC, Guthrie JR, Burger HG, Dennerstein L: Estrogen exposures and memory at midlife: a population-based study of women. Neurology 60, 1369-1371 (2003).
57. Ryan J, Stanczky FZ, Dennerstein L et al.: Hormone levels and cognitive function in postmenopausal midlife women. Neurobiol. Aging (2010) (Epub ahead of print).
58. Clark MS, Dennerstein L, Guthrie JR, Topol BB, Henderson VW: Hormone therapy use in midlife does not influence episodic memory: prospective analyses after natural menopause [abstract]. Neurology 66 (Suppl. 2), A351 (2006).
59. Elias MF, Beiser A, Wolf PA et al.: The preclinical phase of Alzheimers disease: a 22 year prospective study of the Framingham cohort. Arch. Neurol. 57, 808-813 (2000).
60. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P: Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am. J. Epidemiol. 143, 971-978 (1996).
61. Meyer PM, Powell LH, Wilson RS et al.: A population-based longitudinal study of cognitive functioning in the menopausal transition. Neurology 61, 801-806 (2003).
62. Luetters C, Huang MH, Seeman T et al.: Menopause transition stage and endogenous estradiol and follicle-stimulating hormone levels are not related to cognitive performance: cross-sectional results from the study of womens health across the nation (SWAN). J. Womens Health 16, 331-344 (2007).
63. Greendale GA, Huang M-H, Wight RG et al.: Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology 72, 1850-1857 (2009).
64. Fuh J-L, Wang S-J, Lee S-J, Lu S-R, Juang K-D: A longitudinal study of cognition change during early menopausal transition in a rural community. Maturitas 53, 447-453 (2006).
65. Kok HS, Kuh D, Cooper R et al.: Cognitive function across the life course and the menopausal transition in a British birth cohort. Menopause 13, 19-27 (2006).
66. Herlitz A, Thilers P, Habib R: Endogenous estrogen is not associated with cognitive performance before, during or after menopause. Menopause 14, 425-431 (2007).
67. Thilers PP, Macdonald SW, Nilsson LG, Herlitz A: Accelerated postmenopausal cognitive decline is restricted to women with normal BMI: longitudinal evidence from the Betula project. Psychoneuroendocrinology 35, 516-524 (2010).
68. Thilers PP, Macdonald SW, Herlitz A: The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 31, 565-576 (2006).
69. Resnick SM, Henderson VW: Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 288, 2170-2172 (2002).
70. Maki PM: A systematic review of clinical trials of hormone therapy on cognitive function: effects of age at initiation and progestin use. Ann. NY Acad. Sci. 1052, 182-197 (2005).
71. Henderson VW: Estrogen-containing hormone therapy and Alzheimers disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 138, 1031-1039 (2006).
72. Resnick SM, Maki PM, Rapp SR et al.: Effects of combination estrogen plus progestin hormone treatment on cognition and affect. J. Clin. Endocrinol. Metab. 91, 1802-1810 (2006).
73. Resnick SM, Espeland MA, An Y et al.: Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. J. Clin. Endocrinol. Metab. 94, 4152-4161 (2009).
74. Maki PM, Gast MJ, Vieweg A, Burriss SW, Yaffe K: Hormone therapy in menopausal women with cognitive complaints: a randomized, double-blind trial. Neurology 69, 1322-1330 (2007).
75. Kocoska-Maras L, Zethraeus N, Rådestad AF et al.: A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory and spatial ability in healthy postmenopausal women. Fertil. Steril. (2010) (Epub ahead of print).
76. Rocca WA, Grossardt BR, Shuster LT: Oophorectomy, menopause, estrogen, and cognitive aging: the timing hypothesis. Neurodegener. Dis. 7, 163-166 (2010).
77. Rocca WA, Bower JH, Ahlskog JE et al.: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69, 1074-1083 (2007).
78. Sherwin BB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 13, 345-357 (1988).
79. Phillips SM, Sherwin BB: Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology 17, 485-495 (1992).
80. Möller MC, Bartfai AB, Rådestad AF: Effects of testosterone and estrogen replacement on memory function. Menopause 17, 983-989 (2010).
81. Joffe H, Hall JE, Gruber S et al.: Estrogen therapy selectively enhances prefrontal cognitive processes: a randomized, double-blind, placebo-controlled study with functional magnetic resonance imaging in perimenopausal and recently postmenopausal women. Menopause 13, 411-422 (2006).
82. Shumaker SA, Legault C, Rapp SR et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Womens Health Initiative Memory Study (WHIMS). JAMA 289, 2651-2662 (2003).
83. Shumaker SA, Legault C, Kuller L et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Womens Health Initiative Memory Study. JAMA 291, 2947-2958 (2004).
84. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA: Postmenopausal hormone therapy and Alzheimers disease risk: interaction with age. J. Neurol. Neurosurg. Psychiatry 76, 103-105 (2005).
85. Zandi PP, Carlson MC, Plassman BL et al.: Hormone replacement therapy and incidence of Alzheimers disease in older women: the Cache County study. JAMA 288, 2123-2129 (2002).
86. Gibbs RB: Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol. Aging 21, 107-116 (2000).
87. Umetani M, Domoto H, Gormley AK et al.: 27-hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13, 1185-1192 (2007).
88. Clarkson TB: Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis progression. Menopause 14, 373-384 (2007).
89. Sherwood A, Bower JK, McFetridge-Durdle J et al.: Age moderates the short-term effects of transdermal 17b-estradiol on endothelium-dependent vascular function in postmenopausal women. Arterioscler. Thromb. Vasc. Biol. 27, 1782-1787 (2007).
90. North American Menopause Society: Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 17, 242-255 (2010).
91. Santen RJ, Allred DC, Ardoin SP et al.: Postmenopausal hormone therapy: an Endocrine Society scientific statement. J. Clin. Endocrinol. Metab. 95 (Suppl. 1), s1-s66 (2010).
92. Buist DS, Newton KM, Miglioretti DL et al.: Hormone therapy prescribing patterns in the United States. Obstet. Gynecol. 104, 1042-1050 (2004).
93. Paganini-Hill A, Henderson VW: The effects of hormone replace therapy, lipoprotein cholesterol levels, and other factors on a clock drawing task in older women. J. Am. Geriatr. Soc. 44, 818-822 (1996).
94. van Wingen G, van Broekhoven F, Verkes RJ et al.: How progesterone impairs memory for biologically salient stimuli in healthy young women. J. Neurosci. 27, 11416-11423 (2007).
95. Lei ZM, Rao CV: Neural actions of luteinizing hormone and human chorionic gonadotropin. Semin. Reprod. Med. 19, 103-109 (2001).
96. Webber KM, Perry G, Smith MA, Casadesus G: The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin. Med. Res. 5, 177-183 (2007).
97. Hyde Z, Flicker L, Almeida OP et al.: Higher luteinizing hormone is associated with poor memory recall: the health in men study. J. Alzheimers Dis. 19, 943-951 (2010).
98. Rodrigues MA, Verdile G, Foster JK et al.: Gonadotropins and cognition in older women. J. Alzheimers Dis. 13, 267-274 (2008).
99. Mitchell ES, Farin FM, Stapleton PL et al.: Association of estrogen-related polymorphisms with age at menarche, age at final menstrual period and stages of the menopausal transition. Menopause 15, 105-111 (2008).
100. Reichenberg A, Mill J, MacCabe JH: Epigenetics, genomic mutations and cognitive function. Cogn. Neuropsychiatry 14, 377-390 (2009).
101. Seshadri S, Fitzpatrick AL, Ikram MA et al.: Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303, 1832-1840 (2010).
102. Holmes MV, Shah T, Vickery C et al.: Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies. PloS One 2 4(12), e7960 (2009).